Safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth
- 23 February 2023
- journal article
- research article
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. 14 (1) , 45-56
Abstract
The vaginal microbiota is a determinant for the risk of preterm birth (PTB). Dominance of the vaginal niche by Lactobacillus crispatus associates with term delivery. This is the first observational clinical study of live vaginal biotherapeutics (Lactobacillus crispatus CTV-05 (LACTIN-V)) in pregnant women at high-risk of PTB. The primary aim was to explore safety, tolerability and acceptability of LACTIN-V in pregnancy. Women were offered a course of LACTIN-V at 14 weeks gestation for five consecutive days followed by weekly administration for six weeks. Participants were followed up at 15, 18-, 20-, 28- and 36-weeks’ gestation and at delivery for assessment of adverse events, compliance and tolerability. Participants completed a questionnaire to gauge experience and acceptability. In total, 73 women were recruited, of whom eight withdrew, leaving a final cohort size of 61. Self-reported compliance to the course was high (56/60, 93%). Solicited adverse events were reported in 13 women (19%) including changes in vaginal discharge, odour, colour or consistency of urine, itching and vaginal bleeding. One unsolicited adverse event was reported as haematuria at 38 weeks gestation, but was judged to be unrelated to LACTIN-V. No serious adverse events occurred. One mild adverse event led to study withdrawal. Thirty-one women completed an experience and acceptability questionnaire. Women found LACTIN-V easy and comfortable to use and the majority (30/31, 97%) would use LACTIN-V in future pregnancies. Eight women (8/31, 26%) found the schedule of use difficult to remember. The rate of PTB Lactobacillus crispatus CTV-05 and clinical efficacy.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Temporal Dynamics of the Human Vaginal MicrobiotaScience Translational Medicine, 2012
- Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract InfectionClinical Infectious Diseases, 2011
- Phase 2a Study Assessing Colonization Efficiency, Safety, and Acceptability of Lactobacillus crispatus CTV-05 in Women With Bacterial VaginosisSexually Transmitted Diseases, 2010
- Phase 1 Dose-Ranging Safety Trial of Lactobacillus crispatus CTV-05 for the Prevention of Bacterial VaginosisSexually Transmitted Diseases, 2009
- Inhibition of Neisseria gonorrhoeae Epithelial Cell Interactions by Vaginal Lactobacillus SpeciesInfection and Immunity, 2008
- Epidemiology and causes of preterm birthThe Lancet, 2008
- Phase I Trial of aLactobacillus crispatusVaginal Suppository for Prevention of Recurrent Urinary Tract Infection in WomenInfectious Diseases in Obstetrics and Gynecology, 2007
- A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infectionInternational Journal of Antimicrobial Agents, 2006
- Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract floraObstetrics & Gynecology, 2003
- Reduced Incidence of Preterm Delivery with Metronidazole and Erythromycin in Women with Bacterial VaginosisNew England Journal of Medicine, 1995